News

When CRC is HER2+, dual HER2 inhibitor may beat standard EGFR inhibitors

Co-led by the Alliance and SWOG, CTIU2317 compares perioperative versus adjuvant systemic therapy in patients with resectable NSCLC

Those considering PSA screening need data of this sort on risks and benefits of treatment

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment across U.S. and Canada

Longer-term data from SWOG S1826 trial confirm nivolumab-AVD benefit in Hodgkin lymphoma

In surgery for localized muscle-invasive bladder cancer, extended lymph node removal offers no survival benefit but does increase morbidity

A new validated risk model identifies advanced cancer trial patients at highest risk for acute care use

Adding ruxolitinib to TKI treatment for chronic-phase chronic myeloid leukemia (CML) increases deep molecular response rate